Johnson & Johnson $JNJ Shares Sold by Boston Family Office LLC

Key Points

• Boston Family Office LLC reduced its holdings in Johnson & Johnson by 2.0%, now owning 85,219 shares worth approximately $14.13 million.
• Johnson & Johnson recently reported earnings of $2.77 per share, exceeding estimates, with a revenue of $23.74 billion for the quarter.
• The company announced a quarterly dividend of $1.30 to be paid on September 9th, representing an annualized yield of 2.9%.

Boston Family Office LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 85,219 shares of the company's stock after selling 1,742 shares during the period. Boston Family Office LLC's holdings in Johnson & Johnson were worth $14,133,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $49,000. Capital A Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $50,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on JNJ shares. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Bank of America increased their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Trading Up 0.4%

Shares of NYSE:JNJ traded up $0.7820 during trading on Wednesday, reaching $178.5820. 2,801,835 shares of the company were exchanged, compared to its average volume of 9,003,291. The firm has a market capitalization of $430.09 billion, a PE ratio of 19.09, a P/E/G ratio of 2.24 and a beta of 0.41. The business's fifty day simple moving average is $162.13 and its 200-day simple moving average is $158.73. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $180.61. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.